BioMarin Pharmaceutical Inc. 致力開發及推廣針對罕見病及嚴重且危及生命醫療狀況患者的療法。公司總部位於加州聖拉斐爾。
財務指標
營業收入
2026-09-30
$1.02B
2026-06-30
$989.7M
2026-03-31
$766.2M
2025-12-31
$874.56M
營業支出
2026-09-30
$901.31M
2026-06-30
$675.98M
2026-03-31
$441.57M
2025-12-31
$500.08M
淨利潤
2026-09-30
-$122.83M
2026-06-30
$44.76M
2026-03-31
$105.52M
2025-12-31
-$46.57M
淨利潤率
2026-09-30
-11.98%
2026-06-30
4.52%
2026-03-31
13.77%
2025-12-31
-5.32%
每股收益
2026-09-30
$0.02
2026-06-30
$0.90
2026-03-31
$0.76
2025-12-31
$0.46
息稅折舊攤銷前利潤
2026-09-30
$54.32M
2026-06-30
$222.31M
2026-03-31
$172.57M
2025-12-31
-$3.93M
有效稅率
2026-09-30
6.78%
2026-06-30
27.07%
2026-03-31
25.26%
2025-12-31
-71.52%
項目
2026-09-30
2026-06-30
2026-03-31
2025-12-31
營業收入
$1.02B
$989.7M
$766.2M
$874.56M
營業支出
$901.31M
$675.98M
$441.57M
$500.08M
淨利潤
-$122.83M
$44.76M
$105.52M
-$46.57M
淨利潤率
-11.98%
4.52%
13.77%
-5.32%
每股收益
$0.02
$0.90
$0.76
$0.46
息稅折舊攤銷前利潤
$54.32M
$222.31M
$172.57M
-$3.93M
有效稅率
6.78%
27.07%
25.26%
-71.52%
常見問題
BMRN is the ticker symbol for BioMarin Pharmaceutical Inc., a biotechnology company listed on the NASDAQ. The company focuses on developing and commercializing therapies for rare genetic diseases and other serious medical conditions. BMRN stock represents an ownership stake in this biopharmaceutical firm, which has a portfolio of approved treatments and a pipeline of investigational therapies. Investors interested in the healthcare sector may consider BMRN as a potential addition to their watchlist.
Recent performance of BMRN stock can be influenced by a variety of factors, including clinical trial results, regulatory decisions, and broader market trends. For the most current price movements, including daily, weekly, and monthly changes, please refer to the latest BMRN data displayed on this page. The stock's performance may also be affected by company-specific news and developments in the biotechnology sector.
Evaluating BMRN's valuation involves analyzing various financial metrics such as price-to-earnings (P/E), price-to-sales (P/S), and enterprise value ratios. Since BioMarin is a biopharmaceutical company, investors might also consider pipeline potential, revenue growth from approved products, and cash flow trends. Comparing these metrics to industry peers and historical averages can provide context. For updated valuation multiples, please check the latest BMRN data on this page.
BMRN stock can be traded outside regular market hours through pre-market and after-hours sessions. However, these extended trading periods typically have lower liquidity and higher volatility, which may result in wider bid-ask spreads. Not all brokers offer extended-hours trading, so investors should check with their brokerage. For the latest available prices during these sessions, refer to the BMRN data displayed on this page.
BioMarin Pharmaceutical does not currently pay a dividend on its common stock. As a growth-oriented biotechnology company, it typically reinvests earnings into research and development, clinical trials, and commercialization efforts rather than distributing cash to shareholders. Therefore, BMRN is not suitable for income-focused investors seeking dividend income. For any updates on dividend policy, please refer to the latest BMRN data on this page.
Investing in BMRN carries risks common to biotechnology companies, including clinical trial failures, regulatory delays, and the high cost of drug development. Competition from other therapies, pricing pressures, and changes in healthcare policy can also impact performance. Additionally, BMRN's revenue may depend on a limited number of products, making it vulnerable to setbacks. Investors should review the company's risk factors in its SEC filings and consider their own risk tolerance before investing.